TB support in Swaziland


Eswatini (formerly Swaziland) has one of the world’s highest rates of HIV, with nearly one in three adults living with the disease. However, around 80 per cent of people with TB in Eswatini are HIV positive.

Estimates suggest that HIV incidence rates in Eswatini have fallen in recent years, as significant progress has been made in improving the number of people receiving antiretroviral (ARV) treatment.

We continue to help more HIV patients access ARV treatment through the ’test and start’ strategy. A team has been piloting ‘test and start’ in the Nhlangano project; after HIV testing, ARV treatment was offered to more than 1,700 people after a positive HIV diagnosis to immediately start treatment.

We now treat patients with extensively drug-resistant TB (XDR-TB), and those developing severe side effects, using the promising new drugs bedaquiline and delamanid in combination with repurposed drugs.

MSF teams are currently responding to the coronavirus COVID-19 pandemic in Eswatini.

In 2019
Journal article

Impact and programmatic implications of routine viral load monitoring in Swaziland

28 May 2014
Journal article
Swaziland - Born HIV-free

Born HIV-free

Report 17 Sep 2013
Swaziland - Born HIV-free

MSF rolls out innovative medical approach to prevent mother-to-child HIV/AIDS transmission

Project Update 17 Sep 2013
Successful treatment MDR-TB, Mankayane, Swaziland

First group of MDR-TB patients celebrate end of treatment

Project Update 7 Aug 2013
Treating multi drug resistant TB and HIV/AIDS in Manipur, India
Project Update

Historic opportunity to tackle drug-resistant TB demands fast response

Project Update 19 Mar 2013
Swaziland - Figthing HIV and TB dual epidemic

Trying out new approaches to treat HIV

Voices from the Field 28 Nov 2012